Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Evolution in ErbB2-Targeted Therapeutics for Breast Cancer
San Antonio Marriott Riverwalk
San Antonio, TX
December 13, 2008
Saturday, Dec 13, 2008
| 7:30 pm | Registration and Reception |
| 8:00 pm | Welcome, Introductions, and Presession Survey Martine J. Piccart-Gebhart |
| 8:05 pm | Manipulation of the ErbB Axis: Biologic Understandings and Clinical Interpretations Mark Pegram |
| 8:25 pm | Targeted Therapy for Early-Stage Breast Cancer: Lessons Learned and New Directions Martine J. Piccart-Gebhart |
| 8:45 pm | Current Clinical Status and Ongoing Trials of ErbB2-Targeted Therapies in Metastatic Breast Cancer: Accomplishments and New Opportunities Charles E. Geyer, Jr |
| 9:05 pm | Case Management Discussion (A 37-Year-Old Patient With ErbB2-Positive Progressive Liver and Brain Metastases After Combined Modality Treatment) Minetta Liu |
| 9:30 pm | Case Management Discussion (A Patient With Estrogen Receptor–Negative/Progesterone Receptor–Negative/ErbB2-Positive Breast Cancer and Prior ErbB2-Directed Adjuvant Therapy Presenting Two Years Later With Lung Metastases) Hope S. Rugo |
| 9:55 pm | Conclusions and Postsession Survey Mark Pegram |
| 10:00 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- GlaxoSmithKline